A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

"This really has the possibility of ending HIV transmission," said Greg Millett, public policy director at The Foundation for ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...

Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...